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Chapter 1: Abstract 
 
 
The immune response to some pathogenic microorganisms fails to protect the individual 
from severe infection and disease.  Subsets of lymphocytes play a role in the outcome of 
an infection, particularly two subsets of T cells, called T-helper ( TH1 and TH2) 
lymphocytes. When preferentially stimulated, the TH2 cells are often inadequate or 
inappropriate in controlling certain microbes and as a result serious infection develops. 
The TH1 response, on the other hand, may result in the resolution of the severe infection.  
In this study, we attempted to determine if leptin, cyclosporin A (CsA), and/or FK506 
could switch the immune response in Leishmania major infected BALB/c mice from a 
TH2 to a TH1 type response thereby protecting them from severe disease. Groups of mice 
were infected with L. major and treated prophylactically with one of the above three 
drugs. The mice were compared to non-treated, infected animals using a variety of 
observations including ulcer development, footpad size, quantification of L. major in 
tissues and cytokine production. Data suggests that FK506 and CsA are very effective 
immunomodulatory drugs, while the amount of leptin is critical for the balance between 
TH1 and TH2.   
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Leishmania spp. are parasitic protozoa that cause a spectrum of mild to severe cutaneous 
diseases, as well as systemic disease in which severe enlargement of the spleen, liver, and 
lymph nodes occurs. There are about 2 million new cases of leishmaniasis each year and 
a tenth of the world’s population is at risk for this infection (1). This organism is found in 
Africa, the Middle East, South and Central America, and India. The protozoan is 
transmitted by the sand fly, a biting insect belonging to the Phlebotamine or Lutzomyia 
genera. Whereas Leishmania major causes cutaneous ulcers in humans, it causes a 
systemic disease in some strains of inbred mice and is similar to the severe disease 
caused by L. donovani in humans. Although leishmaniasis is an extremely prevalent and 
devastating disease among many people throughout the world, our ability to control this 
disease through drugs or pesticides has proven inadequate. Furthermore our 
understanding of the pathology of these diseases is limited, leaving many unanswered 
questions including mysteries about the immune response to leishamaniasis.  
 The immune response to some pathogenic microorganisms, like Leishmania spp., 
sometimes fails to protect the individual or an entire strain of animals from severe 
infection and disease. Although an immune response is mounted, it is not protective or 
curative, it becomes destructive, causing a systemic infection. When preferentially 
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stimulated, the TH2 cells are often inadequate or inappropriate and result in a failure to 
control certain microbial infections. The TH1 response, on the other hand, may result in 
the resolution of the infection. The balance between these two subsets often determines if 
an infection progresses or resolves itself. This balance is controlled by cytokines secreted 
by the two different subsets of lymphocytes and other cells in the body.  Cytokines 
interact with cellular surface receptors and direct the cells in what to secrete, produce, or 
stop producing.  Essentially, the TH1 subset is stimulated by cytokines produced and 
secreted by other TH1 cells and inhibited by cytokines produced and secreted by TH2 
cells.  The opposite is true for the stimulation and inhibition of the TH2 subset. 
 An inbred strain of mice, called BALB/c, is very susceptible to Leishmania 
major. It is believed that the resulting severe illness is due to the type of response these 
mice mount against the pathogen.  It has been shown that these mice mount a TH2 type 
response resulting in the production of antibodies and B cells that are ineffective against 
the intracellular parasite. It is believed that if this response can be suppressed or reversed, 
and if a TH1 type response is stimulated, increasing cell-mediated immunity, these 
animals would not succumb to the illness. We attempted to accomplish this by treating 
the mice prophylactically with cyclosporin A (CsA), leptin, or FK506.  CsA and FK506 
are commonly regarded as immunosuppressents and leptin, a naturally occurring 
hormone, is an appetite suppressant with immunomodulatory properties. Preliminary 
work in our laboratory has suggested that these treatments alter the susceptibility of these  
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mice and makes them more resistant to sever disease following infection with L. major 
(2). 
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Leishmania 
Leishmania species are obligate intracellular parasites that are found throughout 
the world. Different Leishmania species cause a variety of infections in humans including 
the frequently fatal visceral leishamaniasis or Kala Azar, self healing tropical sores or 
disfiguring mucocutaneous leishmaniasis. Visceral leishmaniasis in humans is 
characterized by fever, weight loss, hepatosplenomegaly, and anemia and is caused by L. 
donovoni. It is often fatal even following treatment and is persistently fatal without 
treatment (1). Mild cutaneous leishmaniasis is characterized by a skin ulcer at the site of 
the sandfly bite. It is usually self-healing within three to six months. A rare form of this 
disease, called diffuse cutaneous leishmaniasis, presents as disseminated skin lesions. An 
uncommon consequence of cutaneous leishmaniasis, which can present itself years after 
the initial skin ulcer heals. It is a metastatic complication of the primary lesion resulting 
in disfiguring and progressive ulceration at the nasal mucocutaneous junction (1). This is 
called mucosal leishmaniasis.  
These diseases are extremely prevalent in Africa, the Middle East, parts of 
Europe, Asia, and in Central and South America. They are transmitted by the sand fly, a 
biting insect belonging to the Phleobotamine or Lutzomyia genera. Although Leishmania  
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major causes a cutaneus form of leishmaniasis in humans, in the mouse it serves as an 
animal model for the severe systemic form of the disease.  
 The sandfly’s natural hosts are rodents, small mammals, and dogs; humans are 
accidental hosts (1).  Upon biting an infected host, the sandfly ingests the amastigote 
form of the parasite. The amastigotes migrate to the hindgut and transform into 
promastigotes, which undergo asexual reproduction (3). The promastigotes are the 
infective form of the parasite. The promastigotes then migrate forward to the esophagus 
of the sandfly, clogging the esophagus. They are inoculated into the victim’s blood 
stream when the sandfly bites and forces the blockage from its system. The promastigotes 
are ingested by the victim’s macrophages and undergo another transformation back into 
amastigotes. The amastigotes asexually reproduce within the macrophage and cause the 
infected macrophage to rupture. The released amastigotes are engulfed by other 
macrophages and the cycle repeats itself (3). 
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Figure 1: The life cycle of Leshmania spp. The sandfly injects the promastigote form of 
the parasite into the skin. Macrophages ingest the promastigotes. The promastigotes 
transform into amastigotes and multiply in the body’s cells. The sandfly ingests 
macrophages infected with amastigotes, the amastigotes transform into the promastigote 
stage in the sandfly’s midgut where they multiply. The promastigotes then migrate to the 
proboscis and the cycle repeats (47). 
 
L. major uses the host complement receptors to gain access to the hostile 
environment of the phagolysosome. Activated macrophages and T-lymphocytes are 
recruited to the site of infection (4). Once inside the phagolysosome, L. major utilizes the 
host-cell’s cyclophilin proteins as part of their replication mechanism (5). Apparently, in 
humans and animals, the outcome of the disease is correlated with the type of T-helper 
response. Resistance is associated with the TH1 response; susceptibility is associated with 
the TH2 response.  The TH1 lymphocytes primarily produce INF- and IL-2 and the TH2  
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lymphocytes primarily produce IL-4 and IL-10.  The TH1 response induces a cell 
mediated (CMI) response whereas the TH2 response induces humoral immunity. CMI is 
the more effective response toward Leishmania because it is an obligate intracellular 
parasite in animals.  It appears that a humoral response has little or no effect on the 
parasite itself because the antibodies produced cannot bind to the intracellular parasite.  
Indeed, even in the presence of high antibody levels, severe systemic disease can 
develop. The depressed TH1 response and the activated TH2 response is an important 
factor in the visceral leishmaniasis disease process. This apparently leads to 
hyperglobulinema, the presence of excessive amounts of antibodies in the blood stream, a 
hallmark characteristic and diagnostic of visceral leishmaniasis (3). 
Visceral leishmaniasis has become increasingly prevalent with the spread of HIV 
(1). With the onset of AIDS, previously “healed” or asymptomatic systemic Leishmania 
infections reactivate. Species that would normally cause only the cutaneous form of the 
disease may present with the visceral form. Co-infections of Leishmania and HIV are 
often resistant to treatment and substantially accelerate the progression of AIDS (1).  
Diagnosis of cutaneous leishmaniasis is accomplished by taking scrapings from 
the edge of an ulcer, staining them with Wright’s or Giemsa’s stain and observing the 
smear microscopically for the parasite in the endothelial cells and the monocytes (3).  
The parasites usually cannot be found in circulating blood.  Cultures are also made in  
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case the amastigotes go undetected in the smear from the scrapings (3).  Treatment is 
usually unnecessary because this form of the disease is normally self-healing.  
Diagnosis of visceral leishmaniasis is accomplished by several techniques. 
Microscopic examination of spleen, liver and other visceral tissues for amastigotes is a 
primary technique (3). Although the production of antibodies by infected individuals does 
not help cure the disease, it is useful in the diagnosis of the disease. Individuals have a 
high titer of IgM, IgG as well as IgE antibodies. Because of the presence of these 
antibodies, ELISA and indirect fluorescet antibody techniques may be used as a 
diagnostic technique. Treatment of visceral leishmaniasis is often sodium stibogluconate 
or pentamidine isthionate (3). Amphotericin B/lipid formulation has been shown to be an 
effective treatment, however it is expensive. Miltefosine, a more affordable treatment, 
and is being used more commonly, however it is not as effective as the more expensive 
treatments (3). These treatments are not only expensive, but they must be administered 
for several weeks and often have serious toxic side effects (3).   
The Immune Response 
 Immunity to pathogenic microorganisms is characterized by both innate resistance 
and acquired immune responses. (6). Innate immunity is not inducible, is always present, 
and is an important but general defense system against pathogens. It includes physical 
barriers like skin, hair, and mucosa, and chemical barriers like lysozymes, and stomach 
acids. Innate immunity is not directed against a specific foreign agent (e.g. pathogen). 
Acquired immunity, however, is gained through immune responses to a specific foreign  
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substance or antigen. It is induced and stimulated by these antigens or immunogens, it 
can change over time and is the basis for vaccinations. Acquired immune responses are 
induced and directed against a specific foreign agent. Essentially acquired immunity has 
the ability to distinguish self from non-self, and is characterized by its inducibility 
specificity, memory, and regulation (6).  
 Acquired immunity is further broken down into two branches, humoral immunity 
and cell mediated immunity (CMI). Humoral immunity is primarily mediated by 
antibodies present in the plasma, lymph and tissue fluids (7).  It is particularly protective 
against extracellular pathogens and toxic macromolecules. There are primarily three 
types of cells involved in the immune response: antigen presenting cells, T helper 
lymphocytes and B cells which actually secrete the antibody.  B cells synthesize and 
display membrane-bound immunoglobulin, or antibody (Ab) molecules which serve as 
receptors for antigens. Following stimulation with antigen and T cell lymphokines, B 
cells differentiate into plasma cells which secrete antibodies, but do not express them on 
their membranes.  Together these cells, and molecules make up the humoral immune 
response. B cells as well as dendritic cells and macrophages also serve as antigen 
presenting cells (APC), which phagocytize antigens, break them down and present the 
antigen to T cells on major histocompatibility complex molecules (MHC).  T cells can 
only recognize antigen after it is processed and displayed on an MHC class I or II 
molecule.  
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MHC molecules interact with T cells, via the T cell receptor (TCR). The TCR is 
the T cell’s membrane bound antigen receptor. Unlike the B cell’s membrane bound 
receptor, the TCR cannot recognize free antigen. Instead it recognizes antigen bound to 
MHC molecules. There are two major types of mature T cells, characterized by 
expression of either CD4
+
 and CD8
+ 
molecules on their cell surfaces
 
(7). CD4 and CD8 
are cell surface markers/receptors. 
 Functionally these cells behave differently.  CD8
+
 T cells bind with antigens 
presented on MHC class I molecules (7). These cells generally function as cytotoxic T 
cells (TC cells) killing virally infected cells. These cells generally recognize endogenous 
peptide antigens.  CD4
+
 T cells bind with antigens presented on MHC class II molecules. 
These cells generally function as T-helper cells (TH cells) helping either other T cells or B 
cells become effecter cells. There are two types of TH cells, TH1 and TH2 cells 
differentiated by the lymphokines they secrete. TH1 clones are involved in cell mediated 
immunity and TH2 clones are predominantly involved in humoral immunity, providing 
cognate B cell help (7).  The two T-helper subsets are controlled by many different 
cytokines. The regulation of these subsets is shown in Figure 2 (7). The subsets 
themselves produce very specific cytokines which, in turn, regulate a specific set of 
immune cells directing the immune response toward humoral or cell-mediated. 
 The balance between TH1 and TH2 often determines the outcome of an infection. 
In many chronic illnesses, a polarized TH1 or TH2 type response occurs, which is  
Shannon M. Potter 
12 
 
 
mutually exclusive response, conceivably because of the counter-inhibitory effects of 
cytokines on the reciprocal TH subsets (8).  Murine TH1 cells produce IL-2 and INF- but 
little IL-4 and IL-5 and have been shown to play an important role in CMI responses 
against intracellular pathogens (9). TH2 cells, on the other hand, produce predominantly 
IL-4, IL-5, and IL-10 but little INF- and are involved in humoral immunity and allergic 
responses (9).   
 
Figure 2: Regulation of 
TH1 and TH2 subsets by cytokines. Each subset of T-cell is regulated by a particular set 
of cytokines.  In turn, each subset produces its own set of cytokines that regulate immune 
cells and direct the type of immune response that occurs.  (7) 
 
 Respiratory syncytial virus (RSV) causes most cases of viral bronchiolitis, which 
is the single most common cause of hospitalization of infants and young children (10).  In  
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the 1960s children were vaccinated with a formalin inactivated virus preparation. 
Unfortunately, this vaccination enhanced the disease process when the child was exposed 
to the virulent virus. The killed virus induced a humoral type response instead of 
inducing a CMI type response. Therefore, the memory acquired by the immune system in 
these vaccinations was a humoral type immunity, which is directed by the TH2 subset. 
This apparently led to an exacerbated inflammatory response when an RSV infection 
occurred. Resolution of the infection is associated with CD4
+
 and CD8
+
 T cells that 
produce INF-. In these resolving infections, only low levels of IL-2, IL-4 and IL-5 were 
detected which suggests a TH1 type immune response. Interestingly, in vitro studies show 
the co-production of IL-4 and INF-, suggesting that the immune response is not always 
completely polarized (10). Field et. al claim that the only evidence for the presence of a 
pure TH1 or TH2 type response is based on clonal proliferation of cells obtained from the 
peripheral blood of patients (11). In most situations, a mixture of responses exists with 
shifts in either direction. 
  The outcome of an HIV infection also seems to be dependent on the type of TH 
response. The presence of specific TH1 type responses in individuals has been shown in 
persons who have been exposed to HIV but are not seropositive for HIV (12).  This 
suggests the presence of HIV-specific protective immunity in these individuals.  Persons 
who live in areas where infectious diseases are endemic seem to have a highly activated 
immune system. Their peripheral blood mononuclear cells were found to secrete 
significantly higher amounts of IL-2, IL-4, IL-10, and soluble TNF receptors and lower  
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amounts of IL-6 in comparison with healthy non-Ethiopian controls (12).  The people of 
these countries (Africa, the middle East, parts of Europe, Asia, and Central and South 
America) are often exposed to helminthic infections early in life (3). It is believed that the 
helmith infections alter the balance between TH1 and TH2 in such a way that makes the 
host more receptive to HIV and more vulnerable to its effects (12). The same is true for 
mycobacteria infections and other intracellular parasitic infections, like leishmaniasis 
(13). However, Maizels et. al. (14) show that helminthic infections steer the immune 
response of the host in the direction of TH2, which is more protective for the host and 
down regulates the TH1 response. Since helminthes are endemic to areas of the world that 
are also endemic to Leshmania spp., Maizels et. al.’s (14) determination could explain 
why some people are immune to leshmaniasis and others become seriously ill.    
Immune Response to Leishmania 
Murine models have been very useful in understanding the visceral disease 
process. Mice resistant to L. major develop a protective immunity by the expansion of 
CD4
+
 TH1 T cells. These protective TH1 cells result from their production of INF-, 
which induces the synthesis of nitric-oxide synthase, (iNOS) (4). Nitric oxide synthase 
leads to the L-arginine-dependent production of reactive nitrogen radicals, which are 
toxic to the intracellular Leishmania parasite. In vitro, this cytotoxicity is dependent on a 
functional Fas-FasL pathway (4). Stenger et. al. have shown that the cutaneous lesion and 
draining lymph nodes of infected, clinically resistant C57BL/6 mice have a detectable 
amount of iNOS earlier during infection and in significantly higher amounts than in  
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infected,  susceptible BALB/c mice (15). Cells isolated from lesions in infected BALB/c 
mice were found to stain positively for transforming growth factor beta (TGF-), a 
powerful inhibitor of iNOS in vitro (15). Susceptible mice develop an early expansion of 
TH2 T-cells. These cells produce IL-4, which appears to be the major inducer for TH2 and 
inhibitor for TH1 type responses (16). Treatment of BALB/c mice with anti-CD4 induced 
resistant to the disease, and restored the expression of iNOS in the tussue (15). This 
response is thought to be due to a parasite antigen that is a Leishmania homolog of 
receptors for activated C kinase, or the LACK antigen. Mice that have been 
transgenically made to express the LACK antigen in the thymus exhibit a diminished TH2 
response and a healing phenotype (16). The type of response that dominates the outcome 
of the infection occurs very early after detection of antigen, like Leishmania’s LACK 
angtigen. CD4
+
 cells specific for the L. major LACK antigen were shown to expand 100-
fold; 70% of those cells were detected to as producers of IL-4 by hour 96 (17). BALB/c 
mice have been specifically shown to produce a burst of IL-4 within the first day of L. 
major infection (18). This early IL-4 production was shown to be a result of the cognate 
recognition of a single epitope in a distinctive antigen, the LACK antigen (18). Schilling 
et. al. (19) have demonstrated that LACK-specific T-cells are active in both the draining 
lymph node and the site of infection, further promoting the rapid replication of the 
parasite and its dissemination to the internal organs.  
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The induction of TH1 dominated or TH2 dominated responses involves a very 
complex interaction between antigen presenting cells, specific antigen epitopes (such as 
the LACK antigen) and T cells. In addition to antigen TCR processing recognition, these 
interactions involve a number of cell surface costimulatory molecules such as CD40, 
CD28, B7molecules and ICOS. Inducer costimulator proteins (ICOS) found on the 
surface of T cells have an important role in T cell induction, stimulation differentiation, 
as well as Ig class switching (20). ICOS is induced by a homolog of CD28 and reacts 
with B7 homolog. It enhances T cell cytokine production, up-regulates the production of 
the CD40 ligand and induces Ig production by B cells. ICOS is induced upon T cell 
receptor engagement with the antigen (20). Whereas another T cell co-stimulator 
molecule, CD28 is constitutively expressed on most T cells (7). Expression of ICOS is 
enhanced by CD28 costimulation. The inducible expression of ICOS suggests that ICOS 
regulates recently activated effecter T cells. Functional studies have suggested that ICOS 
is important for the TH2 response, preferentially inducing IL-4 and IL-10 production. In 
contrast, other studies suggest that ICOS may also regulate the TH1 responses. Greenwald 
et. al. (20) demonstrated that ICOS
-
/
-
 mice infected with Leishmania mexicana exhibited 
pronounced deficits in Ig class switching and T cell cytokine production. Development of 
cutaneous lesions and inflammatory infiltrates was impaired in these mice. This 
demonstrated that ICOS is probably a critical regulator of both the TH1 and TH2 type 
responses in leishmaniasis. It is clear that much more needs to be understood about the 
pathology and immune response to leishmanial infections. 
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Cyclosporin A  
Cyclosporin A (CsA) is a cyclic polypeptide metabolite commercially synthesized 
by the fungus Tolypocladium inflatum with a molecular weight of about 1200 which has 
been shown to have immunosuppressive effects (21).  CsA is a lipophilic compound that 
contains neither free amino nor carboxylic groups. It has a formula of C62H111N11O12 and 
is a cyclic undecapeptide composed of ten amino acids and the unique amino acid N-
methyl-2-amino-3-idroxy-4-methyl-octa-6 enoic acie (MeBmt). With the exception of 
one D-alanine, all of the amino acids are L-series amino acids.  Seven of the amino acids 
have an N-methylation, which is responsible for its lipophilic nature. Stabilization of the 
CsA molecule is maintained by several hydrogen bonds.   CsA is synthesized in a non-
ribosomal biosynthesis pathway (21). A non-ribosomal pathway is directed by a 
multienzyme tiotemplate and without the direct use of nucleic acids (22).  Biosynthesis 
using a non-ribosomal pathway is accomplished by the formation of linear peptidyl 
intermediates which may be enzymatically modified (22). It is thought that CsA is 
biosynthesized in a three step process: i. Synthesis of all building units, ii. Activation of 
the 11 amino acids, and iii. N-methylation and peptide formation (21).  
Toxicity studies show that the selectivity of CsA is for lymphocytes and that there 
is a lack of effect on haemtopoiesis (21).  CsA acts selectively on lymphocytes, mainly T 
cells, affecting particularly the inductive phase of immunity, rather than the proliferative 
phase of immunity. CsA has been shown to alter the balance between T helper  
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lymphocytes and suppressor T-cells. Its immunomodulatroy effects appear to result from 
the inhibition of the production of T-cell derived soluble mediators like IL-2 and IL-3 and 
INF- which leads to an inhibition of primary TH cell activation and blocks the formation 
of lymphokines like IL-2. It also decreases the secretion of INF-. The production of IL- 
and INF-, however does not seem to be affected (21).  T-cell proliferation is inhibited 
by the blockage of Ca2
+
 dependent pathways required for the induction of IL-2 
transcription (23). Complexes of CsA inhibit the calmodulin dependent protein 
phosphatase, calcineurin (24). The calcineurin pathway dephosphorylates the inactive 
cytosolic form of the T cell specific nuclear factor NF-AT, which is a transcription factor 
necessary for T cell activation, See Figure 3 (7).  
 CsA is most commonly used as an immunosuppressant for transplant patients. 
Previous work in our lab has shown that in addition BALB/c mice treated 
prophylactically with CsA have significantly enhanced resistance to L. major infections 
(2).  
FK506  
FK506 is a macrolide that has a molecular weight of about 850 Daltons and is 
produced by a strain of the bacterium Streptomyces (25). It has a molecular formula of 
C44H49NO12H2O.  FK506 has been shown to suppress the immune response both in vivo 
in mice and humans and in vitro it is more potent/mg than that of CsA, and has been  
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shown to suppress the immune system in vitro at about 100 times lower concentration 
than CsA. It also appears to be less toxic than CsA (26).   
FK506, like CsA, has been shown to strongly suppress the humoral immune 
response, possibly by inhibiting the production of T-cell derived soluble mediators (26). 
FK506 especially affects mature CD4
+
 T cell reconstitution in the periphery, seemingly 
by interfering with thymic activation signals such as CD69, which is required for final 
maturation of T cells (27). Both compounds have also been shown to semi-selectively 
spare CD8
+
 T cells (25). These T cells are thought to produce cytokines that act on other 
lymphocytes; for example, these cells produce INF-, which stimulates the TH1 response 
(26).   
FK506 binds to an immunophilin named FKBP-12, or FK506 binding protein 
number 12 (28). Immunophilins serve as receptors to immunosuppressive or 
immunomodulatory drugs. FK506 has also been shown to target the calcineurin pathway 
in a similar manner as Cyclosporin A (Figure 3) (24, 29).  The FK506/FKBP-12 complex 
targets the calcium dependent protein calcineurin. This complex inhibits phosphorylation 
of calcineurin. This inhibition increases the phosphorylation of NOS, a substrate for 
calcineurin; calcineurin dephosphorylates the NOS protein. The phosphorylated 
calcineurin enzyme diminishes its catalystic activity, suppressing the formation of NO2, 
which mediates glutamate neurotoxicity. Tao and Aldskogius (28)  have shown that 
FK506 enhances the survival of damaged nerves by the same pathway . Nitric oxide  
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(NO)  inhibition prevents the glutamate-elicited neurotoxicity. FK506 may exert survival-
promoting effects by decreasing NO synthesis via the inhibition of NOS, which is 
dependent of calcium for its activation (28). Down-regulation of NO, in turn, inhibits 
glutamate release and protects against neurotoxicity. 
 
Figure 3: The Calcineurin Pathway and the Role of CsA and FK506: Calcineurin 
dephosphorylates inactive NFAT, which activates the transcription of cytokine genes. 
CsA and FK506 have been shown to block this pathway by inhibing the 
dephosphorylation of Inactive NFAT. This, in turn, inhibits the transcription of cytokine 
genes (5). 
 
Calcineurin also dephosphorylates the cytoplasmic nuclear factor of activated T 
cells, called NF-ATc (30). This induces its nuclear translocation and eventually forms a 
functional transcription factor that activates the transcription of IL-2. Therefore, FK506 
also inhibits the synthesis and subsequent secretion of IL-2, which is the cytokine that 
induces the clonal proliferation of T cells by suppressing calcineurin’s phosphatase  
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activity. Calcineurin has been shown to co-localize with FKBP-12 in neurons (31). This 
co-localization in the nerve, along with the inhibition of calcineurin by FK506 is believed 
to result in the promotion of neuroregeneration by enhancement of growth-associated 
protein-43 (GAP-43) (32). GAP-43 is a phosphoprotein that has a key role in nerve 
growth, which facilitates neuronal growth after injury. 
Agostinho and Oliveira (33) studied the effect that FK506 and CsA has on 
diseases that are caused by prions in the brain. Prions are proteins that are enriched with 
-sheet conformations, which makes them resistant to proteolytic cleavage by proteases. 
Alzheimer’s disease, the most common form of dementia in the elderly, has been shown 
to be associated with the amyloid beta protein (A) (34). The A protein results from the 
abnormal proteolytic cleavage of amyloid precursor protein. Agostinho and Oliveira (33) 
also studied prio-related encephalopathies (PRE), which are caused by the scrapie 
isoform of prion protein (PrP
Sc
).  Plaques formed by the presence of prions consist of a 
core surrounded by degenerated neuritis, microglia and astorcytic processes. The 
apoptotic pathway of neuronal death appears to be a prominent feature of both 
Alzheimer’s disease and PRE. Apoptosis is thought to be regulated by the calcineurin 
pathway through certain cystine aspartate-specific proteases (caspases). Caspase-3 is 
thought to be a major player in this apoptotic pathway.  Agostinho and Oliveira (33) used 
FK506 to determine if the calcineurin pathway is involved in neuronal death induced by 
the A prion and the PrPSc prion.  They found that FK506 prevented the release of cyt c  
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and thereby prevented the activation of caspase-3. This indicated that this phosphatase is 
involved in the neurotoxic mechanism induced by A and PrPSc. These studies also 
indicated that FK506 did prevent neuronal cell death.  
FK506 is currently being used as an immunosuppressant in transplant patients. It 
has been shown to reduce graft vs. host disease or rejection, which CsA does not (27). 
Previous work in this laboratory has shown that FK506 also significantly enhances the 
resistance to Leishmania major infections in BALB/c mice (unpublished data).  
Leptin 
Leptin is a recently discovered hormone that is secreted exclusively by 
adipocytes. It is a 16-kDa nonglycosylate peptide hormone (35).  The primary amino acid 
sequence of leptin indicates that it may adopt a helical cytokine structure similar to IL-2 
(36). The leptin receptor is expressed not only within the nervous system, but also within 
the immune, hematopoietic, and reproductive systems (37). Leptin induces proliferation, 
differentiation, and functional activation of hemopoietic cells (38). The leptin receptor 
has a sequence homology to the members of the cytokine receptor superfamily (39). It 
also increases the expression of the early activation marker CD69 in monocytes but not in 
lymphocytes. Cytokine production is enhanced, and the basal expression of activation 
markers such as CD38 in human monocytes are stimulated as previously described in the 
LPS stimulation system (33).  Leptin, when given to lean or obese mice, increases basal 
metabolic rate and reduces food intake, leading to weight loss. 
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Leptin has been shown to be essential in balancing the susceptibility to infection 
and autoimmunity, as shown in Figure 4 (39). Normal leptin levels balance the TH1 and 
TH2 response, whereas if leptin levels fall too low, TH1 type responses are reduced and 
TH2 type responses are increased. If too much leptin is present there is a reduced TH1 
type response and an altered inflammatory response.  Circulating levels of leptin are 
proportional to fat mass, but may be lowered rapidly by fasting or increased by an 
inflammatory response (39). An impaired cell mediated type response, or a TH1 type 
response, and reduced leptin levels are both features of low body weight. Starvation or 
malnutrition, which decreases leptin levels, results in the suppression of TH1 mediated 
inflammatory responses (40).  It is well established that nutritional deficiency impairs cell 
mediated immunity, phagocyte function, and cytokine and antibody production (41).  
Both naturally leptin-deficient mice and leptin-receptor-deficient mice, despite 
their great body-fat mass, have thymic and lymph node atrophy, reduced numbers of 
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Figure 4: Leptin’s effect on TH1 vs. TH2 balance. Normal levels of plasma lepitn 
promote a balance between TH1 and TH2 type responses.  Too much leptin or too little 
leptin cause this balance to shift (39). 
 
bone-marrow precursors, and impaired cell mediated immunity (39). In rodents, it has 
been shown that after immunization females have a more vigorous T cell and antibody 
response than males. The presence of estrogens produce higher levels of TH1 cytokines 
and  they show a consistent in vitro secretion of INF- and IL-1 (42). Androgens and 
testosterone produced by males increase the production of IL-4 and IL-5 and switch to 
the TH2 type response (42). Serum levels of leptin are sexually dimorphic, being higher in  
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females than in males (42).  This suggests that leptin is involved in gender-related 
differences in susceptibility.  
Human leptin has been shown to enhance cytokne production by murine 
peritoneal macrophages. Santos-Alvaraz et. al. (37) have demonstrated that human leptin 
stimulates proliferation in a dose-dependent manner and functionally activates human 
circulating monocytes in vitro by inducing the production of cytokines such as TNF- 
and IL-6. The expression of different activation markers in human monocytes, like CD25 
(IL-2 receptor), CD71 (transferring receptor), and CD38 were also increased by leptin in 
a dose-dependent manor. The expression of other activation markers that were already 
present at high levels on the surface of resting monocytes, (e.g. HLA-DR, CD11b, and 
CD11c), were also enhanced by leptin in a dose-dependent manor (37). Santos-Alvaraz 
et. al. (37) also demonstrated that the stimulation of PBMC with leptin produced an 
increase in the percentage of monocytes producing cytokines. The effect of leptin was 
more evident on the population of monocytes producing IL-6, from which about 50% co-
expressed TNF-. However, the population of monocytes producing only TNF- was 
less affected. Therefore a greater effect of leptin on monocyte IL-6 synthesis might be 
expected. The pro-inflammatory response of these cytokines may be enhanced by leptin, 
functioning as an amplification signal for the activation of monocytes. Monocytes are 
activated by leptin through the induction of proliferation expression of activation 
markers, and the production of cytokines.  
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Martín-Romero et. al. (38) have shown that leptin modulates CD4
+
 T lymphocyte 
activation toward the TH1 phenotype by stimulating the synthesis of IL-2 and INF-.  
Leptin receptors are expressed on  both CD4
+
 and CD8
+
 cells, as well as hemopopoetic 
cells, other lymphocytes, and adpocytes. The leptin receptor has a sequence homology to 
members of the cytokine receptor class I superfamily (44).  The receptor has been shown 
to have similar signaling capabilities to that of the IL-6 type cytokine receptor (45).   
Martin-Romero et. al. (38) attempted to determine the effects of human letpin on 
activation, proliferation, and cytokine synthesis in peripheral human lymphocytes. They 
found that a leptin dose-dependent enhances the proliferation and activation of circulating 
T-cells when they were costimulated with either PHA or ConA. Alone, leptin was unable 
to activate T-cells. Leptin also dose-dependently enhanced stimulated CD69 expression; 
late activation markers CD25 and CD71 were also activated by leptin stimulation. Leptin 
modulated CD4
+
 T-cell activation toward the TH1 phenotype by stimulating the 
production of IL-2 and INF-. This shift toward the TH1 phenotype may have some 
relevance in the pathophysiology of immunologic alterations related to obesity. Upon 
measuring the levels of IL-2, INF-, and IL-4, they found that IL-2 and INF- levels were 
increased and that IL-4 was undetectable under the experimental conditions investigated. 
This suggests that leptin levels in the blood stream can easily shift the TH1/TH2 balance. 
According to Lord et. al. (46), “Leptin increases the TH1 and suppresses the TH2 
cytokine production. Without leptin present, the TH2 response is favored; leptin seems to  
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induce the switch to the TH1 response”. Leptin modulates the production of IL-2 and 
INF-, which are TH1 activators (38). Circulating levels of leptin have been found to be 
proportional to fat mass (43).  These levels may be lowered by rapidly fasting or 
increased by inflammatory mediators (47, 48). An impaired cell mediated response and 
reduced levels of leptin have both been found to be features of low body weight in 
humans (49, 50).   
Lord et. al. (46) found that leptin has a specific effect on T-cell responses, 
differentially regulating the proliferation of naïve and memory T-cells. They also tested 
the possibility of leptin influencing TH cytokine production by measuring IL-2, INF-, 
and IL-4 levels in MLR experiments (46). They found that leptin increased IL-2 
production and showed a substantial increase in INF- secretion. IL-4 production was 
completely inhibited, suggesting that leptin may bias T-cell responses towards a TH1 
phenotype and suppress the TH2 phenotype. In the absence of leptin, TH2 responses were 
dominate, the addition of leptin seemed to induce a switch from a TH2 response to a TH1 
response. They also found that T-cells, rather than accessory cells, were the target of 
leptin action. Cognate recognition by T-cell antigen receptor was required before leptin 
could take effect. This indicated that the enhancement of proliferation observed was due 
to a specific effect of leptin receptor signaling rather than to a non-specific mitogenic 
stimulus (46).  
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Mice 
 
 BALB/c mice were originally obtained from Harlan-Sprague Dawley, Inc. 
(Indianapolis, IN) and were bred in our own mouse colony (Department of Biology) .  
Both male and female mice were used with ages ranging from 6 to 12 weeks.  The mice 
were housed in a light and temperature controlled environment with a light/dark cycles of 
approximately 12 hours each.   
Leishmania Infection and Maintenance 
 The Leishmania major (Freidlin strain, NIH) pathogen was originally provided by 
Dr. D. Sacks.  The pathogenicity of the Leishmania was maintained by passage through 
BALB/c mice on a regular basis.  To accomplish this, the mouse was infected via the left 
rear footpad with about 1.0 X 10
6
 organisms per ml.  The infection was allowed to 
progress for two months.  These mice were used as the source of pathogenic L. major by 
removing the spleen and/or popliteal lymph node (located between the knee joint and the 
articular end of the femur) and culturing the cells.  The intracellular amastigote form of L. 
major was released from the hosts’ cells.  These pathogens then developed into the 
infective promastigote form when grown in vitro.  The promastigotes were grown at 25 
C and passed in culture approximately once every week as described below.  
 
Shannon M. Potter 
29 
 
 
The media used to grow the pathogen was Dulbecco’s M199 (Sigma Chemical 
Co., St. Louis MO) amended with 1M HEPES, 10 units penicillin, 10 g/L streptomycin, 
0.35g/L sodium bicarbonate, and 20% fetal calf serum.  The pH of the medium was 
adjusted to 7.2.  For all of the experiments, promastigotes, which had not been passed in 
vitro more than five times, were injected into the left hind footpad with a dose of 1.0 X 
10
6
 organisms per ml.  Over a series of 7 weeks, the middle of the infected footpads were 
measured with a vernier caliper gauge.  The regional draining lymph nodes (popliteal) 
were also palpated to indicate the spread of infection. Swelling of the popliteal lymph 
node was indicative of the spread of infection. 
Cyclosporin A 
 Cyclosporin A (CsA) was originally obtained by Sandoz, Ltd., East Hanover, NJ.  
It arrived prepared as an oral solution at concentration of 100mg/ml in olive oil in a 
labrafil base.  A group of 15 mice, about 12 weeks in ages were each given a dose of CsA 
at 75 µg/g of body weight twice daily for fourteen days, beginning one day prior to 
infection with L. major for both trials.  The CsA was administered using a 20 l pipetmen 
and a plastic tip.  The CsA was squirted into the mouth of the mouse.  The mice were 
weighed before the administration of the drug to determine the dose and to observe the 
effect of the drug on the weight of the mice.  The health of the mice were observed by 
noting the general appearance of the animals, texture of the fur, and the evidence of 
diarrhea in the cages. The animals were observed for smooth, ruffled or oily fur.  
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Leptin 
 Murine leptin was purchased from Sigma Chemical Co., St. Louis, MO.  The 
leptin used was in a solution of 0.2mg/ml in sterile PBS.  During Trial 1, a group of 12 
mice at 8 weeks in age were treated with1.8 g/g of body weight twice daily for five 
days, beginning two days prior to infection.  During trial 2, a group of 15 mice at 8 weeks 
in age were treated with 2.0g/g of body weight twice daily for five days, beginning two 
days prior to infection. The different rates were used due to the fact that level of leptin in 
the body determines the type of TH response (39). The leptin was administered with a ½ 
cc insulin syringe with a 30 gauge needle.  The injections were given intraperitoneally. 
The mice were weighed before the administration of the drug to determine the dose and 
to observe the effect of the drug on the weight of the mice.  The health of the mice was 
observed by noting the general appearance of the animals, texture of the fur, and the 
evidence of diarrhea in the cages, as described above.  
FK506 
 Fujisawa Pharmaceuticals USA, Inc., Aurora, IL generously donated the 
powdered form of FK506.  The powder was reconstituted in 0.2% w/v 
carboxymethylcellulose (CMC) at a concentration of 2.5 mg/ml.  The CMC was prepared 
in a 1% stock solution by dissolving CMC in sterile water.  This solution was then diluted 
to creating a working solution at 0.2% w/v.  A group of seven mice at an age of 8 weeks 
were used for the first trial and a group of 15 mice at an age of 8 weeks were used for the 
second trial.  These mice were given a dose of 50 g/g of body weight once daily for 7  
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days, beginning one day prior to infection.  The FK506 was administered 
intraperitoneally using a 1 cc syringe and a 26-gauge needle.  The mice were weighed 
before the administration of the drug to determine the dose and to observe the effect of 
the drug on the weight of the mice.  The health of the mice were observed as previously 
described. 
Therapeutic FK506 
 FK506 was also used in a small group of mice (5 mice) in a therapeutic treatment 
regimen. These mice, along with a control group (infected, non-treated), were infected 
with 1X10
6
 Leishmania promastigotes/ml.  Fourteen days post infection treatment with 
FK506 was given at a dose of 50 g/g of body weight intraperitoneally using a 1 cc 
syringe and a 26-gauge needle.  Control mice were given 0.2% w/v CMC 
intraperitoneally with a 1 cc syringe and a 26-gauge needle. Both groups were treated 
once daily for seven days.  Health was monitored as described previously.  
Control Mice 
 A group of 20 mice at 16 weeks in age were used as a control group.  These mice 
were given sterile 0.2% w/v CMC intraperitoneally for seven days beginning one day 
prior to infection.  This dose was based on the amount of fluid that would have been 
given if they were in the FK506 group.  It was administered via a 1cc syringe and a 26 
gauge needle. The mice were weighed before the administration of the solution to  
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determine the dose and to observe the effect of the solution on the weight of the mice.  
The health of the mice was observed as described previously.   
Limiting Dilution Assay 
 The limiting dilution assay is based on techniques described by Buffet et al (51).  
One animal from each group was sacrificed either by cervical dislocation or by CO2 
asphyxiation.  The spleen and popliteal lymph node was removed aseptically and placed 
in a sterile petri dish containing 2 ml of complete Dulbecco’s M 199 medium.  Twenty 
milligrams of each organ was aseptically weighed for use in the assay.  To release the L. 
major, each organ was ground between two sterile frosted glass slides.  The ground tissue 
was then placed into 20 ml of complete Dulbecco’s M 199 medium to make a 1mg/ml 
suspension. A duplicate series of 12 sterile tubes containing 2.5 ml of complete 
Dulbecco’s M 199 medium amended with 20% fetal calf serum was prepared.  Zero point 
five milliliters of the stock suspension was placed in the first tube and then 1:6 serially 
diluted.  The tubes were incubated at room temperature (23˚C - 24˚C) for at least 3 
weeks.  The presence of any L. major promastigotes microscopically at 400x indicated a 
positive result for that dilution and represented the minimal most probably number 
(MPN). 
Flow Cytometry Analysis 
 The procedure used in the flow cytometry analysis of lymphocytes extracted from 
the popliteal lymph node was based on Barbara Foster and Calman Prussin’s protocols  
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(52).   Popliteal lymph nodes were removed from three animals in each being tested.  The 
organs were ground between sterile frosted slides and washed in RPMI medium (52). 
Cells were suspended in complete, pre-warmed RPMI at a concentration of 2 X 10
6
 
cells/ml and split into polystyrene round bottomed tubes containing 2 ml each.  Anti-
CD3, anti-CD28 and L. major antigen was added to each tube, and the tubes were 
centrifuged at low speed (300xg) for five minutes to pellet the cells in close proximity 
with each other, the antibodies, and the antigen stimulant. Tubes were then incubated in 
the CO2 incubator at 37 C for 2.5 hours.  A 200µg solution of BFA was added to each 
tube to prevent the export of intracellular cytokines being produced. Cells were then 
incubated for an additional 4 hours. After incubation, cells were washed with 0.1 M 
EDTA and transferred to 4 ml V-bottomed tubes.  The cells were fixed in pre-warmed 
4% Para-formaldehyde, washed again with cold PBS and then resuspended in 10% 
DMSO/PBS.  Cells were counted and placed in freezer vials to be stored at –80 C until 
staining could be performed. 
 The staining of stimulated, frozen cells was also adapted from Prussin’s protocols 
(52). The cells were thawed in a 37 C water bath for 10 minutes. Pre-warmed 25µl PBS-
Saponin (PBS-S) was added to each sample of cells, and the cells were transferred to V-
bottomed tubes. Cells were centrifuged for 10 minutes at high speed (1500xg), and the 
pellet was resuspended in PBS-S/milk. The milk is used to block non-specific binding 
proteins (52).  The cells were then placed on ice for 30 minutes to allow the milk to act as  
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a blocking agent. One tube from each group was chosen as a control tube, and the 
contents of this tube split in-half.  One-half of the cells were resuspended in unlabeled 
monoclonal antibodies against IL-4 and INF-.  The other half was resuspended in non-
specific rat IgG as an isotype control. The rest of the tubes were resuspended in PBS-
S/milk. All tubes were placed on ice for 1 hour. After chilling, labeled antibodies against 
IL-4 and INF- were added to each tube, and the tubes were again placed on ice for 1 
hour, in the dark. Cells were then washed in PBS-S and resuspended in PBS/BSA.  Cells 
were counted in flow cytometer within 24 hours.  
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Effects of drug toxicity on the health of the mice is shown in Table 1.  The 
infected, non-treated mice experienced mild weight loss, mild roughness of the coat, zero 
deaths, and mild diarrhea. The mice treated with CsA, which is known for its toxicity, 
experienced mild to severe weight loss, severe roughness of the coat, zero deaths, and 
severe diarrhea.  After the treatment period ended, the overall appearance of these 
animals returned to normal. Mice treated with FK506 experienced very mild weight loss, 
very mild roughness of the coat, very mild diarrhea, and zero deaths.  Leptin treated mice 
had symptoms that fell in-between the severity of the CsA treated mice and the mildness 
of the FK506 treated mice. 
The measure of footpad thickness was used an indicator used in determining 
disease process. Normal, healthy mice have and average footpad thickness of about 2mm.   
Figure 5 shows the average footpad thickness of mice in each treatment group and the 
non-treated infected group during Trial 1. The control group (non-treated) was challenged 
with L. major but not treated with any immunomodulatory drug. The mice in this group 
experienced a large amount of swelling that dropped of by week 17. This drop in footpad 
thickness was due the large amount of ulceration. Which caused a loss in foot tissue. 
 During trial 2, the dose of leptin was increased from 1.8 g/g of body weight to 
2.0 g/g of body weight. In the first trial, leptin seemed to delay the disease, however, in 
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Table 1 Drug 
Toxicity 
   
Drug Used Observed Weight 
Loss 
Smoothness of Coats 
by Visual Inspection 
Overall Health by 
Visual Inspection 
Controls (0.2% CMC) Mild Mild Roughness Fair, 0 Deaths, Mild 
Diarrhea 
CsA Mild-Severe Severe Roughness Fair, 0 Deaths, Severe 
Diarrhea 
FK506 Very Mild Very Mild  Fair, 0 Deaths, Mild 
Diarrhea 
Leptin Mild Mild Roughness Fair, 0 Deaths, Mild 
Diarrhea 
Table 1: Drug Toxicity.  CsA was the most toxic of the drugs used, mice treated with 
this drug experienced severe diarrhea and mild to severe weight loss during the treatment 
period.  Their fur was also severely ruffled. Mice treated with FK506 developed very 
mild diarrhea and very mild roughness of the fur. Leptin treated mice fell somewhere in-
between, with mild weight loss, mild diarrhea, and mild roughness during the treatment 
period. 
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Figure 5: Average Footpad Thickness for Trail 1
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Figure 5: Average Footpad Thickness of Mice During Trial 1.  Mice treated with 
FK506 developed very little swelling and no ulcers.  Mice treated with CsA were similar 
to mice treated with FK506, little swelling occurred and no ulcer development occurred.  
Mice treated with leptin did experience more swelling and ulcer development.  Non 
treated mice developed large amounts of swelling and ulcer development.  The size of the 
footpads of the non-treated mice dropped due to necrosis of foot tissue.  
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the second trial the mice treated with leptin developed ulcers and swelling weeks before 
the non-treated animals.  The mice treated with CsA experienced little swelling and no 
ulcer development. Mice treated with FK506 did not develop any swelling, redness, or 
ulcer development (Figure 6).   
 To determine parasite load, MPN dilution assays were performed on the draining 
regional lymph node and the spleen of animals from each group. Figure 7 presents 
average titers obtained from the popiteal lymph nodes. Titers were averaged together, 
data without standard error bars are an average of two animals, data with standard error 
bars are an average of four animals. Animals treated with FK506 did not have very high 
parasite loads. The parasite titer did drop in the FK506 animals by week 12.  Animals 
treated with leptin had particularly high parasite titers, which also dropped by week 12.  
The parasite load in animals treated with CsA fluctuated throughout the experiment, but 
never reached levels as high as leptin animals or as low as FK506 animals.  Infected, non-
treated animals had parasite titers that increased fairly steadily with time.  Only the 
spleens of animals in the infected non-treated group and the CsA group had positive 
titers.  These positive results only occurred during weeks 6 and 12 (data not shown). 
 To determine the type of immune response occurring in the FK506 and in the 
infected non-treated animals, flow cytometry analysis of stained intracellular cytokines 
was used.  Later, we also analyzed cells stained for intracellular cytokine production from 
all of the experimental groups.  Figure 8 shows the percent of cells in each sample that  
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Figure 6: Trial 2 Average Footpad Thickness
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Figure 6: Average Footpad Thickness of Mice during Trial 2. FK506 and CsA treated 
mice did not have much swelling and did not develop ulcers. The mice in the leptin 
treated group experienced a large amount of swelling and ulcer development.  The ulcer 
development occurred before the mice in the control, non-treated group.  
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Figure 7: Limitng Dilution Assay of Popliteal 
Lymph Nodes
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Figure 7: Limiting Dilution Assays of Popliteal Lymph Nodes. Data without error bars 
are an average of 2 animals, data with error bars are an average of 4 animals. 
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Figure 8: Amount of Intracellular INF-g Produced
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Figure 8: Amount of INF- produced by mice infected with L. major. Three weeks 
post infection, mice treated with FK506 were producing less INF- than mice that were 
infected but not treated.  By four weeks post infection, the mice treated with FK506 were 
producing slightly more INF-.  By six weeks post infection both the non-treated mice 
and the mice treated with FK506 were producing less INF- than the previous sample, 
however the treated mice were still producing more INF-.  Mice treated with leptin were 
producing about the same amount of INF- as mice treated with FK506. Mice treated 
with CsA were producing the most INF- at six weeks post infection.
Shannon M. Potter 
44 
 
 
were positive for the production of INF-; Figure 9 shows the percent of cells in the 
sample that were positive for IL-4.   
Three weeks post infection; animals treated with FK506 were producing less INF-
 and IL-4 than infected non-treated animals.  These animals were immunosuppressed.  
By four weeks post infection, animals treated with FK506 were producing more INF- 
and less IL-4 than infected non-treated animals, shifting the immune response toward a 
TH1 type response.  Six weeks post infection non-treated animals were producing the 
least amount of INF- and IL-4.  Mice treated with leptin were producing the most 
amount of IL-4, indicating a strong TH2 type immune response. Mice treated with FK506 
or CsA were producing similar amounts of INF-, however the mice treated with FK506 
were producing more IL-4 than mice treated with CsA.  The mice treated with FK506 
never appeared to be ill; their feet did not swell or develop ulcers.  The only sign of 
illness was a swollen poplteal lymph node and a low titer of parasite from that same 
lymph node.  
FK506 was not found to be effective as a therapeutic drug with treatment until  
27 days post infection (Figure 10).  The footpads of the treated mice and the non-treated 
mice began swelling at about the same time.  The non-treated mice did experience 
slightly more swelling than the treated mice.  
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Figure 9: Amount of Intracellular IL-4 Produced
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Figure 9: Amount of IL-4 Produced. Non-treated infected mice produced more IL-4 
than mice treated with FK506 in weeks three and four post infection. Mice treated with 
leptin  produced a large amount of IL-4 at six weeks post infection.  These mice were 
very ill, with large foot pads, large ulcers, and large parasite loads. 
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Figure 10: Average Footpad Thickness of Mice 
Theraputically Treated with FK506
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Figure 10: Average Footpad Thickness of Mice Therapeutically treated with FK506.  
Treated and non-treated mice both developed footpad swelling at about the same time.  
The treated mice displayed a smaller amount of swelling, but not by a large amount.
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FK506 appears to be a very effective drug in preventing severe illness in BALB/c mice 
due to Leishmania major infection.  During both trials, mice treated with FK506 did not 
show any signs of illness.  The footpads of these mice only swelled a small amount.  No 
ulcers were observed during either trial.  As shown in Figure 5, the amount of parasites 
present in these mice was also much less than mice undergoing other treatment regimens.  
These mice were shown to be immunosuppressed three weeks after infection, producing 
very little of either cytokine (Figure 8 and Figure 9).  Four weeks post infection these 
mice were producing much more INF- than the non-treated mice and much less IL-4 
than the non-treated mice (Figure 9).  By six weeks post infection the mice treated with 
FK506 had slowed down production of INF- while IL-4 production remained stable, 
however, the amount of INF- was still greater than the amount of IL-4 being produced 
(Figure 8 and Figure 9).  This suggests that the suppression of the immune response early 
in the disease process inhibited illness.  It also suggests that the type of immune response 
that was occurring later in the disease process was a TH1 type response.  
Due to the success of the first trial, a therapeutic experiment was performed for 
FK506.  Results indicated that this particular treatment plan did not prevent disease 
(Figure 10).  Both sets of mice experience footpad swelling at about day 27 post 
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infection.  At this time, neither set of mice had developed ulcers.  Based on the evidence 
provided in the prophylatic intracellular cytokine data, I believe that if the theraputic 
treatment had been started earlier this result may have been very different. I also believe 
that the response would have been greater had we allowed the experiment to progress 
longer. 
The cyclosporin A group of mice suggested that CsA is effective in preventing the 
mice from developing a severe reaction against the Leishmania infection.  These mice 
experienced weight loss during the treatment period, but readily gained weight after 
treatment ended.  CsA is a toxic drug that has caused death in previous treatment 
regimens (unpublished data), however with the treatment regimen used in both trials, no 
deaths occurred.  Treated mice displayed some ruffling of fur during the treatment period, 
indicating illness caused by toxicity (Table 1).  In the second trial we again saw similar 
toxicity data compared to the first trail.  Although lower doses of cyclosporine may have 
reduced toxicity, unpublished data suggests that they would be below therapeutically 
beneficial levels. 
These mice experienced some swelling of the footpad, which decreased with time 
(Figure 5 and Figure 6).  They also experienced high titers of parasites in their lymph 
nodes, which also seemed to decrease as time passed (Figure 7). We observed cytokine 
production only in week six, and again did not see a major difference between the CsA 
treated animals and the infected, non-treated animals. Mice treated with CsA produced  
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low levels of both cytokines; however, compared to the non-treated animals they were 
producing more INF- (Figure 8).  These mice produced about the same amount of IL-4 
as the infected non-treated mice (Figure 9).  The larger INF- production suggests that 
treatment with CsA pushes the immune response toward a TH1 type response.  
Mice in the leptin group fell somewhere between resistance and delay of illness 
during the first trial. They did not experience any weight loss or ruffling of the fur (Table 
1). However they did appear to have an increased amount of footpad swelling and ulcer 
development (Figure 5). They also exhibited a large titer of parasites in their lymph nodes 
but small titer in their spleens.  In the second trial the dose of leptin was increased. 
During the second trial the balance between TH1 and TH2 seemed to be shifted. Mice 
developed ulcers and a large amount of footpad swelling before the infected non-treated 
animals (Figure 6). Again, we observed cytokine production only in week six, and did not 
see a significant difference between the leptin treated animals and the infected non-
treated animals.  Animals were producing more IL-4 than INF- six weeks post infection 
(Figure 8 and Figure 9).  The production of more IL-4 would indicate that leptin was 
pushing the immune response towards a TH2 type response.   
 Based on the data presented, I believe that the immune response against 
Leishmania major infection in BALB/c mice is responsible for either systemic disease or 
resistance to the disease.  Mice given FK506, which suppressed the immune system early 
in the infection, never showed signs or symptoms of illness (Table 1, Figures 5, 6, 7, 8,  
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and 9).  The footpads of these mice did not swell or develop ulcers.  Their fur remained 
smooth, and their parasite load remained low.  Data suggests that resistance to 
leishmaniasis is determined early after infection.  Future experiments should assay, cells 
from each group of animals earlier in the disease process.  I would also recommend that 
therapeutic treatment using FK506 begin earlier after infection.   
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